


REMARKS

The subject case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty. The above amendment to the specification is being made to reference the priority document.

New Claims 17 and 18 are supported by the specification on page 11, lines 16-18, and page 15, line 31, to page 16, line 8. The insertion of "a pharmaceutically acceptable salt thereof" into Claims 2-12 is supported by Claim 1, on which these claims depend.

Applicants respectfully submit that the application is allowable, and a favorable response from the Examiner is earnestly solicited.

Respectfully submitted,

By 

James L. McGinnis
Reg. No. 34,387
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: July 19, 2006